Multi-Attribute Method (MAM) is a mass spectrometry-based method that allows site specific monitoring of product quality attributes and impurity detection (new peak detection) for biotherapeutics. It has become a household name for many pharmaceutical
companies as they apply the technique at various stages of development from sequence optimization to quality control settings. At any stage of development, improved speed and precision is paramount for the method to have an impact and to shorten
the duration of the development. In this presentation, we describe our recent development in automated MAM sample preparation using SizeX IMCStips® & Hamilton Microlab® STAR.
We evaluated robustness by varying sample concentration and precision of the data by comparing results for samples generated using automated sample preparation against manually prepared samples. The key findings were: 1) improved sample recovery and
consistency at the buffer exchange step, 2) minimal sample preparation induced modifications, 3) similar or better precision for all attributes monitored. Overall, we found the automated sample preparation is suitable to replace traditional manual
preparation allowing for higher throughput and a reduction of time at the bench.
At the end of this webinar, participants would be able to:
- Identify processes and workflows that would benefit from Multi-Attribute Method (MAM)
- Compare and contrast the automated MAM approach with manual preparation methods
- Explore potential avenues for implementing automated MAM in their own laboratories
Yuko Ogata, PhD
Senior Scientist, Analytical
Evotec Biologics, Inc.
Yuko is a Senior Scientist in the mass spectrometry group at Just-Evotec Biologics (Seattle, WA), an integrated design company focused on technologies that accelerate development of biotherapeutics and substantially reduce their manufacturing cost.
The Multi-Attribute Method (MAM) is an integral technology used at all stages of drug development in achieving these goals.
Before joining Just-Evotec in 2017, Yuko spent nearly 10 years as a key member of two proteomics core labs (Center for Global Infectious Research Center and Fred Hutchinson Cancer Research Center). Prior to her work in proteomics labs, Yuko’s
post-doctoral study in Prof. David Muddiman’s group at Mayo Clinic involved proteomic studies of low-abundance proteins and their post-translational modifications in human cerebrospinal fluid and plasma. Yuko obtained her Ph.D. in analytical
chemistry/mass spectrometry at University of Washington (mentor: Prof. Frantisek Turecek) where she developed an automated frontal affinity chromatography system with a renewable assay surface for screening compound mixtures against immobilized
proteins. During her time in these labs, Yuko authored or co-authored 23 peer-reviewed publications.
Richard S. Rogers, PhD
Dr. Rogers received his Ph.D. from the Johns Hopkins University in 2003. His research focused on SUMO modification of transcription factors. As a post doc, Dr. Rogers joined the Institute for Systems Biology. At the ISB, Dr. Rogers expanded his research
on post translational modification by applying mass spectrometry to detect phosphorylation and other ubiquitin-like modifications in macrophages. In 2012, Dr. Rogers joined the Analytical Sciences group at Amgen. At Amgen, Dr. Rogers developed
a mass spectrometry based multi-attribute method (MAM) for biotherapeutic characterization and release from QC. At Just Biotherapeutics, Dr. Rogers continued his work on MAM and started the MAM Consortium. Dr. Rogers is currently exploring the
uses of MAM for cell-based therapies at Juno Therapeutics (a Bristol-Myers Squibb company) in Seattle.